Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia
First gene therapy RMAT designation for an inherited retinal disease STAR Phase 3 registrational trial ongoing and FDA interactions planned RMAT designation enables closer and more frequent multidisciplinary interaction with FDA with all of the benefits of …